Q-omics provides the consensus-scored MRAP-AS1 profile across patient tissues and cancer cell-line models. MRAP-AS1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MRAP-AS1 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, MRAP-AS1 RNA expression shows 15,253 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, BRCA, and THYM as cancer lineages where MRAP-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRAP-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRAP-AS1 survival associations across molecular data types. MRAP-AS1 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRAP-AS1 RNA expression–survival associations across cancer types. High MRAP-AS1 expression shows unfavorable associations in UVM, LUAD, LGG and THCA, but favorable associations in READ and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MRAP-AS1 RNA expression.
This table summarizes MRAP-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MRAP-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRAP-AS1 shows lower tumor expression in BRCA and higher tumor expression in KIRC and COAD. The BRCA box plot shows higher MRAP-AS1 RNA expression in normal versus tumor tissue (log2 FC = −0.404, t-test p < 0.001).
This table shows molecular features associated with MRAP-AS1 in patient tissues and cancer cell lines. In patient samples, MRAP-AS1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
